David C Binder
Overview
Explore the profile of David C Binder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
755
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhai L, Ladomersky E, Lauing K, Wu M, Scholtens D, Savoor R, et al.
Oncoimmunology
. 2019 Feb;
8(3):1548242.
PMID: 30723577
Preclinical modeling and gene expression analyses have yielded distinct observations for the role of immune checkpoint, IDO1, in glioblastoma (GBM). Accordingly, our recent work differs with Garg . (2017) with...
2.
Binder D, Ladomersky E, Lenzen A, Zhai L, Lauing K, Otto-Meyer S, et al.
Transl Cancer Res
. 2018 Oct;
7(Suppl 4):S510-S513.
PMID: 30283731
No abstract available.
3.
Ladomersky E, Zhai L, Lenzen A, Lauing K, Qian J, Scholtens D, et al.
Clin Cancer Res
. 2018 Mar;
24(11):2559-2573.
PMID: 29500275
Glioblastoma is the most aggressive primary brain tumor in adults with a median survival of 15-20 months. Numerous approaches and novel therapeutics for treating glioblastoma have been investigated in the...
4.
Stokes W, Binder D, Jones B, Oweida A, Liu A, Rusthoven C, et al.
J Neuroimmunol
. 2017 Nov;
313:118-122.
PMID: 29153603
Background: Patients with melanoma brain metastases (MBM) have been excluded from trials evaluating immunotherapy in melanoma. As such, immunotherapy's role in MBM is poorly understood, particularly in combination with radiotherapy....
5.
Zhai L, Ladomersky E, Lauing K, Wu M, Genet M, Gritsina G, et al.
Clin Cancer Res
. 2017 Jul;
23(21):6650-6660.
PMID: 28751450
Indoleamine 2,3 dioxygenase 1 (IDO1) mediates potent immunosuppression in multiple preclinical models of cancer. However, the basis for elevated IDO1 expression in human cancer, including the most common primary malignant...
6.
Binder D, Wainwright D
Trends Mol Med
. 2017 Jun;
23(7):580-582.
PMID: 28583420
Salmonella Typhimurium, engineered to express flagellin B, recently demonstrated unprecedented tumor control through a TLR-dependent mechanism. Here, we review new observations that support the potential of utilizing modified bacteria to...
7.
Zhai L, Ladomersky E, Dostal C, Lauing K, Swoap K, Billingham L, et al.
Brain Behav Immun
. 2017 Feb;
62:24-29.
PMID: 28179106
Glioblastoma (GBM) is the most common malignant brain tumor in adults with a median survival of 14.6months. A contributing factor to GBM aggressiveness is the intratumoral expression of the potently...
8.
Ladomersky E, Genet M, Zhai L, Gritsina G, Lauing K, Lulla R, et al.
Oncoimmunology
. 2016 Sep;
5(8):e1196311.
PMID: 27622066
The effective treatment of adult and pediatric malignant glioma is a significant clinical challenge. In adults, glioblastoma (GBM) accounts for the majority of malignant glioma diagnoses with a median survival...
9.
Binder D, Arina A, Wen F, Tu T, Zhao M, Hoffman R, et al.
Oncoimmunology
. 2016 Jul;
5(6):e1130207.
PMID: 27471609
We recently reported that therapeutic vaccination with live tumor antigen-producing Salmonella typhimurium rescues dysfunctional endogenous T cell responses and eradicates long-established tumors refractory to αCTLA-4 and αPD-L1 checkpoint inhibitor blockade....
10.
Binder D, Davis A, Wainwright D
Oncoimmunology
. 2016 Apr;
5(2):e1082027.
PMID: 27057463
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and still remains incurable. Although immunotherapeutic vaccination against GBM has demonstrated immune-stimulating activity with some promising survival benefits,...